JAIDS Journal of Acquired Immune Deficiency Syndromes · 2018 · 18 citations · 20 references
Life SciencesInfectious DiseasesMicrobiologyClinical MedicineInfectious Disease EpidemiologyVirologyAntiretroviral TherapyAntiviral Drug ResistanceAntiviral ResistanceAntiviral TherapyHiv EpidemiologyHiv TestingAntiretroviral AccessDrug Resistance MonitoringHiv ArtHiv PrevalenceMolecular Drug ResistanceTransmitted Drug ResistanceViral Load AssaysViral Load Assessment
BACKGROUND: Little is known about prevalence of drug resistance among HIV-infected Ugandans, a setting with over 15 years of public sector access to antiretroviral therapy (ART) and where virological monitoring was only recently introduced. SETTING: This study was conducted in the adults' out-patient clinic of the Infectious Diseases Institute, Kampala, Uganda. METHODS: HIV genotyping was performed in ART-naive patients and in treatment-experienced patients on ART for ≥6 months with virological failure (≥1000 copies/mL). RESULTS: A total of 152 ART-naive and 2430 ART-experienced patients were included. Transmitted drug resistance was detected in 9 (5.9%) patients. After a median time on ART of 4.7 years [interquartile range: 2.5-8.7], 190 patients (7.8%) had virological failure with a median viral load of 4.4 log10 copies per milliliter (interquartile range: 3.9-4.9). In addition, 146 patients had a viral load between 51 and 999 copies per milliliter. Most patients with virological failure (142, 74.7%) were on first-line ART. For 163 (85.8%) ART-experienced patients, genotype results were available. Relevant drug-resistance mutations were observed in 135 (82.8%), of which 103 (63.2%) had resistance to 2 drug classes, and 11 (6.7%) had resistance to all drug classes available in Uganda. CONCLUSION: The prevalence of transmitted drug resistance was lower than recently reported by the WHO. With 92% of all patients virologically suppressed on ART, the prevalence of virological failure was low when a cutoff of 1000 copies per milliliter is applied, and is in line with the third of the 90-90-90 UNAIDS targets. However, most failing patients had developed multiclass drug resistance.
20
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
Huldrych F. Günthard, Michael S. Saag, Constance A. Benson et al. · JAMA · 2016 · 656 citations · Full text
Ravindra K. Gupta, Michael R. Jordan, Binta Sultan et al. · The Lancet · 2012 · 368 citations
Public Health, Infectious Disease Control, Pharmacotherapy +11
John Gregson, Michele W. Tang, Nicaise Ndembi et al. · The Lancet Infectious Diseases · 2016 · 275 citations · Full text
Lucas E. Hermans, Michelle Moorhouse, Sergio Carmona et al. · The Lancet Infectious Diseases · 2017 · 170 citations · Full text
Amin S. Hassan, Helen Nabwera, Shalton Mwaringa et al. · AIDS Research and Therapy · 2014 · 105 citations · Full text